Generex Biotechnology: First Metformin Gum Patent Granted to Generex Biotechnology
14th Nov 2006, 18:04 GMT
TORONTO (MARKET WIRE) Generex Biotechnology Corporation (NASDAQ: GNBT), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, announced today that it has been granted the first patent for its medicinal gum platform titled "Compositions for Oral Transmucosal Delivery of Metformin." The patent covers claims to the composition, processes, and methodologies for the delivery of an oral transmucosal
Generex Biotechnology: First Metformin Gum Patent Granted to Generex Biotechnology related news:
- 1st Metformin Gum Patent Granted to Generex Biotech — Operations-Related News from StratCenter.com
- First Metformin Gum Patent — The Diabetes Blog
- ProactiveNet Granted U.S. Patent for Correlation and Root Cause of Performance Events and Abnormalities — ArriveNet : Technology
- ProactiveNet: ProactiveNet Granted U.S. Patent for Correlation and Root Cause of Performance Events and Abnormalities — Market Wire - Computers and Software
- United Therapeutics subsidiary settles patent dispute — bizjournals.com Health Care:Biotechnology headlines
- / CORRECTION - Industrial Biotechnology Corporation — ArriveNet : Health
- 100 years of customer service — PittsburghLIVE.com
- SpectraScience files new patent application — News-Medical News Feed
- Industrial Biotechnology Corp.: / CORRECTION - Industrial Biotechnology Corporation — Market Wire - Trade Shows/Seminars
- From the Labs: Biotechnology — Technology Review Feed - BioTech Top Stories
Latest news from Market Wire - Pharmaceuticals and Biotech:
- Qiagen N.V.: QIAGEN Introduces Novel Technology for Customized RNAi Assay Products
- IBEX TECHNOLOGIES INC.: IBEX: Analysis of Urinary C2C Distinguishes Between Individuals with Painful Knees and Individuals Identified by MRI to Have Early Osteoarthritis
- Daiichi Sankyo, Inc.: First Study to Evaluate WelChol/Ezetimibe and Simvastatin Effect on LDL-C Finds Additional Lipid Parameter Benefits
- Daiichi Sankyo, Inc.: WelChol and Ezetimibe Combination Therapy Provides Significant LDL-C Reductions
- Targeted Genetics Corporation: Interim Data on Use of tgAAC94 in the Treatment of Inflammatory Arthritis Presented at the American College of Rheumatology Meeting
- Crucell N.V.: Crucell Announces Third Quarter 2006 Results
- Acambis PLC: Acambis PLC announces Update on US MVA procurement
- SkyePharma PLC: SkyePharma PLC announces Board Appointment
- Base Technologies, Inc.: Base Technologies Award of Air Force Surgeon General Contract Continues Rapid Growth Trend
- Eugene Science, Inc.: Eugene Science Signs Major Distribution Agreement With RexGene Biotech